This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fogelman, I. Articles by Reginster, J.-Y. Search for Related Content PubMed PubMed Citation Articles by Fogelman, I. Articles by Reginster, J.-Y.

Risedronate Reverses Bone Loss in Postmenopausal Women with Low Bone Mass: Results From a Multinational, Double-Blind, Placebo-Controlled Trial¹

Department of Nuclear Medicine (I.F.), Guy’s Hospital, London SE1 9RT, United Kingdom; Department of Endocrinology (C.R.), Hospital Rangueil, Toulouse 31403, France; Oxford Health Management Ltd. (R.S.), Acland Hospital, Oxford S10 2RX, United Kingdom; Procter & Gamble Pharmaceuticals (D.E., E.S.), Mason, Ohio 45040; and Bone/Cartilage Metabolism Unit (J.-Y.R.), Polycliniques L. Brull, 4020 Liege, Belgium

Address correspondence and requests for reprints to: Ignac Fogelman, Department of Nuclear Medicine, Guy’s Hospital, St. Thomas Street, London SE1 9RT, United Kingdom.

Our objective was to investigate the efficacy and tolerability of risedronate in postmenopausal women with low bone mass.

Women with a mean lumbar spine T-score of -2 or less (n = 543) received 24 months of placebo or risedronate (2.5 or 5 mg/day). All received calcium (1 g/day). The principal outcome measures were bone mineral density (BMD) at the lumbar spine, femoral neck, and femoral trochanter.

At 24 months, lumbar spine BMD increased from baseline by 4% with 5 mg risedronate and 1.4% in the 2.5-mg group, compared with no change with placebo. Efficacy was similar in women who were less than 5 yr and more than 5 yr postmenopausal. At 24 months, risedronate (5 mg) had also increased BMD at the femoral neck and trochanter, whereas BMD decreased in the placebo group. BMD increases were seen at all three sites with risedronate (5 mg) after only 6 months of therapy. Risedronate was well tolerated; upper gastrointestinal adverse events were similar to placebo.

We conclude that risedronate (5 mg) increases BMD rapidly and effectively and is well tolerated in postmenopausal women with low bone mass, regardless of time since menopause.

This article has been cited by other articles:

				L. Graat-Verboom, E. F. M. Wouters, F. W. J. M. Smeenk, B. E. E. M. van den Borne, R. Lunde, and M. A. Spruit Current status of research on osteoporosis in COPD: a systematic review Eur. Respir. J., July 1, 2009; 34(1): 209 - 218. [Abstract] [Full Text] [PDF]

				E. P Weiss, K. Shah, L. Fontana, C. P Lambert, J. O Holloszy, and D. T Villareal Dehydroepiandrosterone replacement therapy in older adults: 1- and 2-y effects on bone Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1459 - 1467. [Abstract] [Full Text] [PDF]

				A. Lipton Toward New Horizons: The Future of Bisphosphonate Therapy Oncologist, September 1, 2004; 9(suppl_4): 38 - 47. [Abstract] [Full Text] [PDF]

				S. F Eichner, K. B Lloyd, and E. M Timpe Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment Ann. Pharmacother., May 1, 2003; 37(5): 711 - 724. [Abstract] [Full Text] [PDF]

				J. P. Brown and R. G. Josse Lignes directrices de pratique clinique 2002 pour le diagnostic et le traitement de l'osteoporose au Canada Can. Med. Assoc. J., March 18, 2003; 168(90060): SF1 - 38. [Abstract] [Full Text] [PDF]

				B. L. Riggs and L. C. Hartmann Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629. [Full Text] [PDF]

				N. B. Watts, R. G. Josse, R. C. Hamdy, R. A. Hughes, M. D. Manhart, I. Barton, D. Calligeros, and D. Felsenberg Risedronate Prevents New Vertebral Fractures in Postmenopausal Women at High Risk J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 542 - 549. [Abstract] [Full Text] [PDF]

				M. J. Horwitz, M. B. Tedesco, C. Gundberg, A. Garcia-Ocana, and A. F. Stewart Short-Term, High-Dose Parathyroid Hormone-Related Protein as a Skeletal Anabolic Agent for the Treatment of Postmenopausal Osteoporosis J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 569 - 575. [Abstract] [Full Text] [PDF]

				J. T. Lin and J. M. Lane Bisphosphonates J. Am. Acad. Ortho. Surg., January 1, 2003; 11(1): 1 - 4. [Full Text] [PDF]

				J. P. Brown and R. G. Josse 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada Can. Med. Assoc. J., November 12, 2002; 167(90100): s1 - 34. [Abstract] [Full Text] [PDF]

				H. Taggart, M. A. Bolognese, R. Lindsay, M. P. Ettinger, H. Mulder, R. G. Josse, A. Roberts, H. Zippel, S. Adami, T. F. Ernst, et al. Upper Gastrointestinal Tract Safety of Risedronate: A Pooled Analysis of 9 Clinical Trials Mayo Clin. Proc., March 1, 2002; 77(3): 262 - 270. [Abstract] [PDF]

				C. Crandall Risedronate: A Clinical Review Arch Intern Med, February 12, 2001; 161(3): 353 - 360. [Abstract] [Full Text] [PDF]